Cadwalader Represents Credit Suisse in Connection With AcelRx Pharmaceuticals’ $65 Million Monetization of Expected Royalty Stream From Zalviso™

Sep 21, 2015

Cadwalader  is pleased to announce it represented Credit Suisse in a transaction for which Credit Suisse was the sole structuring and financial advisor to AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) in the monetization of the expected royalty stream from the sales of Zalviso™ (sufentanil sublingual tablet system) in the European Union by its commercial partner Grunenthal GmbH. AcelRx, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that gross proceeds from the sale are $65 million.

The Cadwalader team included Christopher Cox, Corporate; Ira Schacter and Steve Lenkowsky, Capital Markets; Dorothy Auth, Intellectual Property; and David Miller, Tax.  

CadwaladerSpotlight

IMN's 6th Annual Investors' Conference on European CLOs and Leveraged Loans

Nick Shiren and Daniel Tobias will be speaking at this key industry event on April 2 in London.

Cadwalader's research and intelligence platform provides analysis on changes in U.S. financial regulation. Subscribers receive a daily newsletter interpreting new laws, rules and enforcement actions that impact financial institutions.